Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains

Vaccine

Volumn 34, Issue 51, 2016, Pages 6610-6616

  Condit, Richard C ^a   Williamson, Anna Lise ^b   Sheets, Rebecca ^c   Seligman, Stephen J ^d,e   Monath, Thomas P ^f   Excler, Jean Louis ^g   Gurwith, Marc ^h   Bok, Karin ⁱ   Robertson, James S ^j   Kim, Denny ^k   Michael Hendry, R ^l   Singh, Vidisha ^l   Mac, Lisa M ^l   Chen, Robert T ^l  

^a UNIVERSITY OF FLORIDA   (United States)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f Kleiner Perkins Caufield & Byers   (United States)

^g US Military HIV Research Program (MHRP)   (United States)

^h PaxVax Inc   (United States)

ⁱ U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^j NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^k Takeda Vaccines   (United States)

^l CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

Brighton Collaboration; Live viral vaccines; Potential for recombination; Vaccine manufacturing; Vaccine safety; Vaccines; Virus recombination

Indexed keywords

LIVE VACCINE; VIRUS VACCINE; VIRUS VECTOR; DRUG CARRIER;

ARTICLE; DRUG SAFETY; HOST RANGE; HUMAN; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINATION REACTION; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD TYPE; ANIMAL; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; VIRULENCE; VIRUS;

ANIMALS; DRUG CARRIERS; GENETIC VECTORS; HUMANS; RECOMBINATION, GENETIC; VACCINES, ATTENUATED; VIRAL VACCINES; VIRULENCE; VIRUSES;

EID: 85000938291     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.04.060     Document Type: Article

References (78)

1. [1] Chen, R.T., Carbery, B., Mac, L., Berns, K.I., Chapman, L., Condit, R.C., et al. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine 33 (2015), 73–75.
2. [2] World Health Organization, WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors. 2003.
3. [3] World Health Organization, WHO informal consultation: development of viral vectored vaccines for HIV, malaria, tuberculosis and other indications. 2013.
4. [4] European Medicines Agency, Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. 2010.
5. [5] U.S. Food and Drug Administration, Determining the need for and content of environmental assessments for gene therapies, vectored vaccines, and related recombinant viral or microbial products; guidance for industry. 2015.
6. [6] Appaiahgari, M.B., Vrati, S., Clinical development of IMOJEV (R) – a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 12 (2012), 1251–1263.
7. [7] Villar, L., Dayan, G.H., Arredondo-Garcia, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372 (2015), 113–123.
8. [8] Capeding, M.R., Tran, N.H., Hadinegoro, S.R., Ismail, H.I., Chotpitayasunondh, T., Chua, M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet, 2014.
9. [9] Hadinegoro, S.R., Arredondo-Garcia, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
10. [10] Monath, T.P., McCarthy, K., Bedford, P., Johnson, C.T., Nichols, R., Yoksan, S., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20 (2002), 1004–1018.
11. [11] Meeusen, E.N., Walker, J., Peters, A., Pastoret, P.P., Jungersen, G., Current status of veterinary vaccines. Clin Microbiol Rev 20 (2007), 489–510 Table.
12. [12] Phan, T.G., Okitsu, S., Maneekarn, N., Ushijima, H., Evidence of intragenic recombination in G1 rotavirus VP7 genes. J Virol 81 (2007), 10188–10194.
13. [13] Plyusnin, A., Kukkonen, S.K., Plyusnina, A., Vapalahti, O., Vaheri, A., Transfection-mediated generation of functionally competent Tula hantavirus with recombinant S RNA segment. EMBO J 21 (2002), 1497–1503.
14. [14] Ramig, R.F., Ward, R.L., Genomic segment reassortment in rotaviruses and other reoviridae. Adv Virus Res 39 (1991), 163–207.
15. [15] Steinhauer, D.A., Skehel, J.J., Genetics of influenza viruses. Annu Rev Genet 36 (2002), 305–332.
16. [16] Suzuki, Y., Gojobori, T., Nakagomi, O., Intragenic recombinations in rotaviruses. FEBS Lett 427 (1998), 183–187.
17. [17] Han, G.Z., He, C.Q., Ding, N.Z., Ma, L.Y., Identification of a natural multi-recombinant of Newcastle disease virus. Virology 371 (2008), 54–60.
18. [18] Perez-Ramirez, G., Diaz-Badillo, A., Camacho-Nuez, M., Cisneros, A., Munoz, M.L., Multiple recombinants in two dengue virus, serotype-2 isolates from patients from Oaxaca, Mexico. BMC Microbiol, 9, 2009, 260.
19. [19] Chen, S.P., Yu, M., Jiang, T., Deng, Y.Q., Qin, C.F., Han, J.F., et al. Identification of a recombinant dengue virus type 1 with 3 recombination regions in natural populations in Guangdong province, China. Arch Virol 153 (2008), 1175–1179.
20. [20] Barr, J.N., Fearns, R., How RNA viruses maintain their genome integrity. J Gen Virol 91 (2010), 1373–1387.
21. [21] Hahn, C.S., Lustig, S., Strauss, E.G., Strauss, J.H., Western equine encephalitis virus is a recombinant virus. Proc Natl Acad Sci U S A 85 (1988), 5997–6001.
22. [22] Hu, W.S., Temin, H.M., Effect of gamma radiation on retroviral recombination. J Virol 66 (1992), 4457–4463.
23. [23] Keck, J.G., Stohlman, S.A., Soe, L.H., Makino, S., Lai, M.M., Multiple recombination sites at the 5′-end of murine coronavirus RNA. Virology 156 (1987), 331–341.
24. [24] Kirkegaard, K., Baltimore, D., The mechanism of RNA recombination in poliovirus. Cell 47 (1986), 433–443.
25. [25] Lai, M.M., RNA recombination in animal and plant viruses. Microbiol Rev 56 (1992), 61–79.
26. [26] Lai, M.M., Genetic recombination in RNA viruses. Curr Top Microbiol Immunol 176 (1992), 21–32.
27. [27] Worobey, M., Holmes, E.C., Evolutionary aspects of recombination in RNA viruses. J Gen Virol 80:Pt 10 (1999), 2535–2543.
28. [28] Aaskov, J., Buzacott, K., Field, E., Lowry, K., Berlioz-Arthaud, A., Holmes, E.C., Multiple recombinant dengue type 1 viruses in an isolate from a dengue patient. J Gen Virol 88 (2007), 3334–3340.
29. [29] Chuang, C.K., Chen, W.J., Experimental evidence that RNA recombination occurs in the Japanese encephalitis virus. Virology 394 (2009), 286–297.
30. [30] Twiddy, S.S., Holmes, E.C., The extent of homologous recombination in members of the genus Flavivirus. J Gen Virol 84 (2003), 429–440.
31. [31] Chare, E.R., Gould, E.A., Holmes, E.C., Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol 84 (2003), 2691–2703.
32. [32] Cooper, P.D., Genetics of picornaviruses. Fraenkel-Conrat, H., Wagner, R.R., (eds.) Comprehensive virology, 1977, Plenum Press, New York, 133–207.
33. [33] Smyth, R.P., Davenport, M.P., Mak, J., The origin of genetic diversity in HIV-1. Virus Res 169 (2012), 415–429.
34. [34] Norberg, P., Depledge, D.P., Kundu, S., Atkinson, C., Brown, J., Haque, T., et al. Recombination of globally circulating varicella-zoster virus. J Virol 89 (2015), 7133–7146.
35. [35] Moussatche, N., Damaso, C.R., McFadden, G., When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J Infect Dev Ctries 2 (2008), 156–173.
36. [36] Dispas, M., Schynts, F., Lemaire, M., Letellier, C., Vanopdenbosch, E., Thiry, E., et al. Isolation of a glycoprotein E-deleted bovine herpesvirus type 1 strain in the field. Vet Rec 153 (2003), 209–212.
37. [37] Chong, Y.L., Padhi, A., Hudson, P.J., Poss, M., The effect of vaccination on the evolution and population dynamics of avian paramyxovirus-1. PLoS Pathog, 6, 2010, e1000872.
38. [38] Kew, O.M., Wright, P.F., Agol, V.I., Delpeyroux, F., Shimizu, H., Nathanson, N., et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 82 (2004), 16–23.
39. [39] Grobbelaar, A.A., Weyer, J., Leman, P.A., Kemp, A., Paweska, J.T., Swanepoel, R., Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 17 (2011), 2270–2276.
40. [40] Becher, P., Orlich, M., Thiel, H.J., RNA recombination between persisting pestivirus and a vaccine strain: generation of cytopathogenic virus and induction of lethal disease. J Virol 75 (2001), 6256–6264.
41. [41] Camus-Bouclainville, C., Gretillat, M., Py, R., Gelfi, J., Guerin, J.L., Bertagnoli, S., Genome sequence of SG33 strain and recombination between wild-type and vaccine myxoma viruses. Emerg Infect Dis 17 (2011), 633–638.
42. [42] Wenhui, L., Zhongyan, W., Guanqun, Z., Zhili, L., JingYun, M., Qingmei, X., et al. Complete genome sequence of a novel variant porcine reproductive and respiratory syndrome virus (PRRSV) strain: evidence for recombination between vaccine and wild-type PRRSV strains. J Virol, 86, 2012, 9543.
43. [43] Lee, S.W., Markham, P.F., Coppo, M.J., Legione, A.R., Markham, J.F., Noormohammadi, A.H., et al. Attenuated vaccines can recombine to form virulent field viruses. Science, 337, 2012, 188.
44. [44] Niewiadomska, A.M., Gifford, R.J., The extraordinary evolutionary history of the reticuloendotheliosis viruses. PLoS Biol, 11, 2013, e1001642.
45. [45] Slate, D., Algeo, T.P., Nelson, K.M., Chipman, R.B., Donovan, D., Blanton, J.D., et al. Oral rabies vaccination in north america: opportunities, complexities, and challenges. PLoS Negl Trop Dis, 3, 2009, e549.
46. [46] Monath, T.P., Kanesa-Thasan, N., Guirakhoo, F., Pugachev, K., Almond, J., Lang, J., et al. Recombination and flavivirus vaccines: a commentary. Vaccine 23 (2005), 2956–2958.
47. [47] Seligman, S.J., Gould, E.A., Live flavivirus vaccines: reasons for caution. Lancet 363 (2004), 2073–2075.
48. [48] Seligman, S.J., Gould, E.A., Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis 198 (2008), 794–795.
49. [49] Collins, P.L., Bukreyev, A., Murphy, B.R., What are the risks – hypothetical and observed – of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?. J Virol 82 (2008), 9805–9806.
50. [50] Han, G.Z., Liu, X.P., Li, S.S., Caution about Newcastle disease virus-based live attenuated vaccine. J Virol, 82, 2008, 6782.
51. [51] Hai, R., Garcia-Sastre, A., Swayne, D.E., Palese, P., A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains. J Virol 85 (2011), 6832–6843.
52. [52] Mueller, S., Papamichail, D., Coleman, J.R., Skiena, S., Wimmer, E., Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 80 (2006), 9687–9696.
53. [53] Coleman, J.R., Papamichail, D., Skiena, S., Futcher, B., Wimmer, E., Mueller, S., Virus attenuation by genome-scale changes in codon pair bias. Science 320 (2008), 1784–1787.
54. [54] Pitisuttithum, P., Rerks-Ngarm, S., Bussaratid, V., Dhitavat, J., Maekanantawat, W., Pungpak, S., et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS ONE, 6, 2011, e27837.
55. [55] Ball, L.A., Pringle, C.R., Flanagan, B., Perepelitsa, V.P., Wertz, G.W., Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73 (1999), 4705–4712.
56. [56] Clarke, D.K., Nasar, F., Lee, M., Johnson, J.E., Wright, K., Calderon, P., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 81 (2007), 2056–2064.
57. [57] Clarke, D.K., Nasar, F., Chong, S., Johnson, J.E., Coleman, J.W., Lee, M., et al. Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol 88 (2014), 6690–6701.
58. [58] Dudek, T., Knipe, D.M., Replication-defective viruses as vaccines and vaccine vectors. Virology 344 (2006), 230–239.
59. [59] Nitayaphan, S., Pitisuttithum, P., Karnasuta, C., Eamsila, C., de, S.M., Morgan, P., et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 190 (2004), 702–706.
60. [60] Fries, L.F., Tartaglia, J., Taylor, J., Kauffman, E.K., Meignier, B., Paoletti, E., et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 (1996), 428–434.
61. [61] Gilbert, S.C., Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 31 (2013), 4241–4246.
62. [62] Youil, R., Toner, T.J., Su, Q., Casimiro, D., Shiver, J.W., Chen, L., et al. Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses. Hum Gene Ther 14 (2003), 1017–1034.
63. [63] Jackson, R.J., Ramsay, A.J., Christensen, C.D., Beaton, S., Hall, D.F., Ramshaw, I.A., Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75 (2001), 1205–1210.
64. [64] Chen, N., Bellone, C.J., Schriewer, J., Owens, G., Fredrickson, T., Parker, S., et al. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy. Virology 409 (2011), 328–337.
65. [65] Qin, L., Liang, M., Evans, D.H., Genomic analysis of vaccinia virus strain TianTan provides new insights into the evolution and evolutionary relationships between Orthopoxviruses. Virology 442 (2013), 59–66.
66. [66] Liu, Z., Wang, S., Zhang, Q., Tian, M., Hou, J., Wang, R., et al. Deletion of C7L and K1L genes leads to significantly decreased virulence of recombinant vaccinia virus TianTan. PLOS ONE, 8, 2013, e68115.
67. [67] Liu, Q., Li, Y., Luo, Z., Yang, G., Liu, Y., Liu, Y., et al. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. AIDS 29 (2015), 649–658.
68. [68] Xiao, H., Liu, L., Zhu, Q., Tan, Z., Yu, W., Tang, X., et al. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLOS ONE, 8, 2013, e83274.
69. [69] Wen, B., Deng, Y., Chen, H., Guan, J., Chuai, X., Ruan, L., et al. The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques. Mol Ther 21 (2013), 1787–1795.
70. [70] Gurwith, M., Lock, M., Taylor, E.M., Ishioka, G., Alexander, J., Mayall, T., et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13 (2013), 238–250.
71. [71] Radin, J.M., Hawksworth, A.W., Blair, P.J., Faix, D.J., Raman, R., Russell, K.L., et al. Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines. Clin Infect Dis 59 (2014), 962–968.
72. [72] Weaver, E.A., Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors. Hum Vaccin Immunother 10 (2014), 544–556.
73. [73] Guy, B., Guirakhoo, F., Barban, V., Higgs, S., Monath, T.P., Lang, J., Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28 (2010), 632–649.
74. [74] McGee, C.E., Tsetsarkin, K.A., Guy, B., Lang, J., Plante, K., Vanlandingham, D.L., et al. Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLoS ONE, 6, 2011, e23247.
75. [75] Taucher, C., Berger, A., Mandl, C.W., A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination. J Virol 84 (2010), 599–611.
76. [76] McGee, C.E., Tsetsarkin, K., Vanlandingham, D.L., McElroy, K.L., Lang, J., Guy, B., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 197 (2008), 686–692.
77. [77] McGee, C.E., Lewis, M.G., Claire, M.S., Wagner, W., Lang, J., Guy, B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 197 (2008), 693–697.
78. [78] Monath, T.P., Seligman, S.J., Robertson, J.S., Guy, B., Hayes, E.B., Condit, R.C., et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33 (2015), 62–72.